| Primary |
| Plasma Cell Myeloma |
36.4% |
| Prophylaxis |
22.7% |
| Pain |
13.6% |
| Dyspnoea |
9.1% |
| Polyuria |
9.1% |
| Non-small Cell Lung Cancer |
4.5% |
| Pathologic Fracture Of Vertebrae |
4.5% |
|
| Vomiting |
50.0% |
| Blood Potassium Increased |
25.0% |
| Unresponsive To Stimuli |
25.0% |
|
| Secondary |
| Multiple Myeloma |
12.3% |
| Plasma Cell Myeloma |
7.5% |
| Prophylaxis |
7.5% |
| Chemotherapy |
6.1% |
| Breast Cancer |
5.6% |
| Hypertension |
5.6% |
| Prophylaxis Of Nausea And Vomiting |
5.6% |
| Glaucoma |
5.0% |
| Osteoporosis |
5.0% |
| Pain |
4.5% |
| Anticoagulant Therapy |
4.2% |
| Colon Cancer |
4.2% |
| Premedication |
4.2% |
| Chronic Lymphocytic Leukaemia |
3.9% |
| Mantle Cell Lymphoma |
3.6% |
| Epilepsy |
3.4% |
| Myeloma Recurrence |
3.4% |
| Product Used For Unknown Indication |
3.1% |
| Diverticulitis |
2.8% |
| Antiviral Prophylaxis |
2.5% |
|
| Cardiac Failure |
8.7% |
| Thrombocytopenia |
8.7% |
| Diverticulitis |
7.2% |
| Sepsis |
7.2% |
| Syncope |
7.2% |
| Vomiting |
7.2% |
| Dyspnoea |
5.8% |
| Osteonecrosis |
5.8% |
| Gastrointestinal Stromal Tumour |
4.3% |
| Pain In Extremity |
4.3% |
| Plasmacytoma |
4.3% |
| Posterior Reversible Encephalopathy Syndrome |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Diabetes Mellitus |
2.9% |
| Hyperthyroidism |
2.9% |
| Pain |
2.9% |
| Pyrexia |
2.9% |
| Sudden Death |
2.9% |
| Systemic Mycosis |
2.9% |
| Tendon Rupture |
2.9% |
|
| Concomitant |
| Colorectal Cancer |
12.9% |
| Drug Use For Unknown Indication |
9.4% |
| Hypertension |
8.6% |
| Prophylaxis |
8.3% |
| Non-small Cell Lung Cancer |
7.1% |
| Vomiting |
7.0% |
| Prophylaxis Of Nausea And Vomiting |
6.6% |
| Abdominal Pain |
5.9% |
| Product Used For Unknown Indication |
5.2% |
| Breast Cancer |
5.1% |
| Thrombosis Prophylaxis |
3.2% |
| Pain |
2.9% |
| Nausea |
2.8% |
| Tumour Pain |
2.8% |
| Diarrhoea |
2.6% |
| Premedication |
2.2% |
| Glioblastoma |
2.0% |
| Goitre |
2.0% |
| Chest Pain |
1.8% |
| Constipation |
1.6% |
|
| Wound Infection |
10.1% |
| Pulmonary Embolism |
8.7% |
| Vomiting |
8.7% |
| Pyrexia |
7.5% |
| Thrombocytopenia |
7.5% |
| Sepsis |
5.2% |
| Tremor |
5.2% |
| General Physical Health Deterioration |
4.9% |
| Pneumonia |
4.9% |
| White Blood Cell Count Decreased |
4.1% |
| Febrile Neutropenia |
3.8% |
| Respiratory Failure |
3.8% |
| Somnolence |
3.8% |
| Weight Decreased |
3.5% |
| Hepatic Enzyme Increased |
3.2% |
| Tachycardia |
3.2% |
| Urinary Tract Infection |
3.2% |
| Mucosal Inflammation |
2.9% |
| Rapid Correction Of Hyponatraemia |
2.9% |
| Tumour Haemorrhage |
2.9% |
|
| Interacting |
| Drug Use For Unknown Indication |
41.2% |
| Metastatic Renal Cell Carcinoma |
11.8% |
| Renal Cancer Metastatic |
11.8% |
| Renal Cell Carcinoma Stage Unspecified |
11.8% |
| Brain Oedema |
5.9% |
| Epilepsy |
5.9% |
| Metastases To Central Nervous System |
5.9% |
| Metastases To Lung |
5.9% |
|
| Gastric Ulcer Perforation |
25.0% |
| White Blood Cell Count Increased |
25.0% |
| Drug Interaction |
12.5% |
| Haematemesis |
12.5% |
| Hyperglycaemic Hyperosmolar Nonketotic Syndrome |
12.5% |
| Metastatic Renal Cell Carcinoma |
12.5% |
|
